Medicare ACO Participants Hit Firewall

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.

November 25th 2025

Phase 2b Trial Shows Vixarelimab Improves Itch and Lesions in Prurigo Nodularis

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

Vixarelimab shows rapid, sustained symptom relief and improved lesions in prurigo nodularis patients. | Image Credit: @this_baker-AdobeStock.jpeg

December 19th 2025

Home Health Care Delivery, Outcomes Vary by Payment Model: Rachel A. Prusynski, DPT, PhD

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

November 18th 2025

Rachel A. Prusynski, DPT, PhD, discusses her study on how payment models affect home health care delivery and patient outcomes.

Listen

Unmet health-related social needs, like housing and transportation, are associated with higher ED and inpatient use, highlighting opportunities for targeted interventions. | Image credit: @indysystem-AdobeStock.jpeg

ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.

As ACA subsidies expire, experts warn coverage losses may strain behavioral health access and increase emergency department boarding and uncompensated care. | Image credit: @Yurii Kibalnik-Adobestock.jpeg

ICYMI: Highlights From ASCO 2025

With ACA subsidies expiring, experts warn coverage losses could worsen access to behavioral health care and emergency department strains.

Related Content

December 22nd 2025

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.

November 25th 2025

Phase 2b Trial Shows Vixarelimab Improves Itch and Lesions in Prurigo Nodularis

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

December 19th 2025

Home Health Care Delivery, Outcomes Vary by Payment Model: Rachel A. Prusynski, DPT, PhD

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

November 18th 2025

Rachel A. Prusynski, DPT, PhD, discusses her study on how payment models affect home health care delivery and patient outcomes.

Listen

ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.